医学
免疫疗法
恶性肿瘤
肿瘤科
内科学
临床试验
基底细胞
癌症
癌症研究
免疫学
作者
Ning Chen,Xiaoling Xu,Yun Fan
标识
DOI:10.1177/17588359231189420
摘要
Oesophageal squamous cell carcinoma (ESCC) is a kind of malignant tumour with high invasiveness and a poor prognosis. Immunotherapy, especially immune checkpoint inhibitors (ICIs), is a rapidly growing therapeutic method that activates and enhances anti-tumour immunity to treat patients with malignancy. Several clinical trials have confirmed the efficacy of ICIs in the treatment of ESCC. ICIs have been approved for the treatment of patients with ESCC. However, only a subset of patients can obtain excellent benefits from ICI therapy. In recent years, there has been a growing interest in exploring predictive biomarkers of immunotherapy response. In this review, we highlighted the predictive biomarkers for the prognosis of ESCC patients treated with ICIs and pointed out the existing problems and the direction of future research in this field.
科研通智能强力驱动
Strongly Powered by AbleSci AI